Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Corgenix Diagnostic Ebola Test Research Earns Abstract Award

By LabMedica International staff writers
Posted on 01 Aug 2014
The Best Annual Meeting Abstract Award is given by the AACC Critical and Point-of-Care Testing Division in recognition of outstanding research for abstracts submitted and posters presented at the AACC annual meeting.

The Ebola research award and Lassa fever oral abstract of Corgenix Medical (Broomfield, CO, USA) receive the award recognized for its high quality poster abstract, “Development of a Point-of-Care Diagnostic for Ebola and Sudan Virus Detection,” presented at the AACC conference. More...
Douglass Simpson, BS, MS, Corgenix president and CEO comments, “We’re pleased to accept this prestigious award, and we must also recognize our academic, research, and industry partners at the Viral Hemorrhagic Fever Consortium (VHFC), who have helped to make this possible. We are continuing with our efforts to develop breakthrough diagnostic products for detecting Ebola, Lassa, and other biologic agents. Rapid, accurate testing for these agents in difficult environments is critical to global public health and defense against bioterrorism threats.”

Corgenix and the VHFC were recently awarded a three-year, USD 2.9 million National Institutes of Health (NIH) grant to continue work on the development of an Ebola rapid diagnostic test kit. Corgenix and the consortium have already developed and CE marked the ReLASV rapid diagnostic test for the Lassa fever virus.

The current Ebola outbreak in West Africa is the largest ever recorded. Mr. Simpson said that it is clear that point-of-care (POC) testing will be needed in the future for the rapid identification and treatment of viral hemorrhagic fevers, including Lassa, Ebola, and Marburg.

Corgenix is also presenting an oral abstract titled “Suspected Lassa Fever (LF) Case Outcomes: A Comparison to a Non-Febrile Population in Sierra Leone.” The study was conducted to better identify and treat patients with Lassa, which can be difficult to distinguish from other illnesses such as malaria. Study results are being presented by Corgenix Regulatory and Clinical Affairs Specialist Bethany Belote and will be published in the October issue of Clinical Chemistry.

Related Links:

Corgenix Medical
National Institutes of Health



Gold Member
Blood Gas Analyzer
Stat Profile pHOx
Collection and Transport System
PurSafe Plus®
Hemodynamic System Monitor
OptoMonitor
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: LungCanSeek demonstrated an overall sensitivity of 83.5% and specificity of 90.3% in detecting lung cancer (Photo courtesy of AdobeStock)

New Blood Test Offers Affordable and Accurate Early Detection of Lung Cancer

Lung cancer remains the leading cause of cancer-related deaths worldwide, largely because most cases are diagnosed at advanced stages when treatment options are limited. Early detection significantly improves... Read more

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The TriVerity IVD test includes the TriVerity cartridge and the Myrna instrument (Photo courtesy of Inflammatix)

Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients

When a patient enters the emergency department in critical condition, clinicians must rapidly decide whether the patient has an infection, whether it is bacterial or viral, and whether immediate treatment... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.